Is MNKD a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

5,111 people get MNKD articles and Market Currents by email alert.

Get email alerts on MNKD »

HEADLINES:

Arena Buyout More 'Highly Probable' Than MannKind
Chris_Roberts • Thu, May 23 • 31 Comments
MannKind's Afrezza And The Oramed Threat
Cory Renauer • Thu, May 23 • 25 Comments
Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 81 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 51 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 30 Comments
MannKind Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9 • 6 Comments
MannKind Corporation Reports 2013 First Quarter Financial Results

Business Wire (May 9, 2013)
MannKind to Present at Bank of America Merrill Lynch 2013 Health Care Conference

Business Wire (May 8, 2013)
MannKind Corporation to Hold 2013 First Quarter Financial Results Conference Call on May 9, 2013

Business Wire (May 2, 2013)
Insiders Are Buying These 9 Environmentally Conscious Stocks
Kapitall • Fri, Apr 26
Bullish Insider Buying Activity Surfacing Among These Names In Real Estate, Healthcare
Insightful Investor • Tue, Apr 16 • 8 Comments
Healthcare Sector Trends May Be Shifting Towards Boutique Pharmacy Services
VFC's Stock House • Tue, Apr 16 • 3 Comments
MannKind's Afrezza Likely To Easily Gain Approval
Joe Springer • Mon, Apr 15 • 152 Comments
2 Biotechs With A Strong Risk Of Failure
Equity Options Guru • Sun, Apr 14 • 73 Comments
MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial
Brian L. Wilson • Thu, Apr 11 • 107 Comments
Minimizing Risk When Investing In Biopharmas
Healthcare Specialist • Wed, Apr 10 • 17 Comments
Tech And Healthcare: Eye Catching Themes Of Early April
D. Mero • Tue, Apr 9 • 17 Comments
3 Biopharmas With Significant Potential
Healthcare Specialist • Thu, Apr 4 • 21 Comments
My 2Q 2013 Diversified REIT Portfolio Designed For Outperformance
Dane Bowler • Wed, Apr 3 • 34 Comments
Biotech: Hedging While Speculating
Nathaniel Munson • Fri, Mar 29 • 36 Comments

5 Reasons MannKind Could Be The Best Performing Stock Of 2013
Joe Springer • Fri, Mar 8 • 219 Comments

MannKind's Afrezza And The Oramed Threat
Cory Renauer • Thu, May 23 • 25 Comments
Pricing A Highly Probable Takeover Of MannKind
George Rho • Wed, May 22 • 81 Comments
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • Sat, May 18 • 30 Comments
MannKind's Afrezza Likely To Easily Gain Approval
Joe Springer • Mon, Apr 15 • 152 Comments
MannKind's Afrezza Likely To Fail AFFINITY 1 Phase III Trial
Brian L. Wilson • Thu, Apr 11 • 107 Comments
MannKind: A Pure Speculative Bet
Efsinvestment • Wed, Mar 20 • 52 Comments
5 Reasons MannKind Could Be The Best Performing Stock Of 2013
Joe Springer • Fri, Mar 8 • 219 Comments
An Excellent Biotech Bet For 2013
Stock Whisper • Wed, Dec 26, 2012 • 6 Comments
Long Mannkind? How To Make Money While In Queue
Clayton Rulli • Fri, Dec 21, 2012 • 2 Comments
3 Ways To Trade MannKind - Given 2013 Will Be A Huge Success Or A Complete Failure
Rodney Watson • Tue, Dec 18, 2012 • 23 Comments
Long MannKind's Afrezza: Shares Versus A Bull Call Spread
Clayton Rulli • Sat, Dec 1, 2012 • 45 Comments
With Share Offering Registration And Trial Enrollment Complete, Time To Buy MannKind
Rx Stocks • Fri, Oct 12, 2012 • 16 Comments
3 Reasons This Speculative Bio-Pharma Is A Winner
Joe Springer • Fri, Aug 10, 2012 • 77 Comments
MannKind Fights On With Its Diabetes Game-Changer Afrezza
Praveen Jayarajan • Fri, Jul 6, 2012 • 31 Comments
MannKind: If You Buy, When?
Rx Stocks • Wed, Jun 27, 2012 • 14 Comments
Why Mannkind Has Long-Term Value
Spencer Knight • Wed, May 23, 2012 • 10 Comments
MannKind: Will The Good News Ever Come?
Douglas W. House • Wed, Apr 25, 2012 • 15 Comments
The Curious Case Of MannKind Corporation
Scott Matusow • Tue, Jan 31, 2012 • 8 Comments
Another Small Step Back For Mannkind
Spencer Knight • Tue, Jan 31, 2012 • 6 Comments
MannKind Is Simply Running Out Of Cash
Martin Shkreli • Thu, Jan 19, 2012 • 81 Comments

Arena Buyout More 'Highly Probable' Than MannKind
Chris_Roberts • Thu, May 23 • 31 Comments
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 51 Comments
Insiders Are Buying These 9 Environmentally Conscious Stocks
Kapitall • Fri, Apr 26
Bullish Insider Buying Activity Surfacing Among These Names In Real Estate, Healthcare
Insightful Investor • Tue, Apr 16 • 8 Comments
Healthcare Sector Trends May Be Shifting Towards Boutique Pharmacy Services
VFC's Stock House • Tue, Apr 16 • 3 Comments
2 Biotechs With A Strong Risk Of Failure
Equity Options Guru • Sun, Apr 14 • 73 Comments
Minimizing Risk When Investing In Biopharmas
Healthcare Specialist • Wed, Apr 10 • 17 Comments
Tech And Healthcare: Eye Catching Themes Of Early April
D. Mero • Tue, Apr 9 • 17 Comments
3 Biopharmas With Significant Potential
Healthcare Specialist • Thu, Apr 4 • 21 Comments
My 2Q 2013 Diversified REIT Portfolio Designed For Outperformance
Dane Bowler • Wed, Apr 3 • 34 Comments
Biotech: Hedging While Speculating
Nathaniel Munson • Fri, Mar 29 • 36 Comments
Several Big Growth Stories In Biotech: Keith Markey
Life Sciences Report • Thu, Mar 28 • 5 Comments
Cramer's Mad Money - Whoever Loses The Dell Bidding War Is The Winner (3/26/13)
SA Editor Miriam Metzinger • Wed, Mar 27 • 2 Comments
Mannkind, SanuWave, AntriaBio: Speculatively Investing In Next Generation Diabetes Treatments
VFC's Stock House • Wed, Mar 13 • 3 Comments
Weekly Stock Watch, Week Of 11 March 2013
VFC's Stock House • Mon, Mar 11 • 13 Comments
MAP's Levadex Ready For FDA Approval
Beacon VP Investments • Sun, Feb 3 • 10 Comments
VIX - Options Volatility And Market Sonar: Friday Recap
Erick McKitterick • Fri, Jan 25 • 6 Comments
4 Rallying Biotech Stocks Being Snapped Up By Insiders
Kapitall • Wed, Jan 16 • 2 Comments
Identifying Stocks That May Double Within A Year
Marc Courtenay • Tue, Jan 15 • 3 Comments
Insiders Love These 3 Highly Shorted Biotech Stocks
Kapitall • Tue, Jan 8 • 1 Comment

MannKind Corporation's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 9 • 6 Comments
MannKind Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 11 • 2 Comments
MannKind Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 1, 2012
MannKind's CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012
MannKind's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Wed, May 9, 2012 • 5 Comments
MannKind's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 22, 2012
MannKind's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Nov 4, 2011
MannKind's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Aug 5, 2011
MannKind's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Mon, May 9, 2011 • 3 Comments
MannKind CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 10, 2011
MannKind CEO Discusses Q3 2010 Results – Earnings Call Transcript
Fri, Oct 29, 2010
Mannkind Corp. Q2 2010 Earnings Call Transcript
Mon, Aug 2, 2010 • 4 Comments
MannKind Corporation Q1 2010 Earnings Call Transcript
Fri, Apr 30, 2010
MannKind Corporation Q4 2009 Earnings Call Transcript
Tue, Feb 2, 2010 • 2 Comments
MannKind Corporation Q3 2009 Earnings Call Transcript
Mon, Nov 2, 2009
MannKind Corporation Q2 2009 Earnings Call Transcript
Mon, Aug 3, 2009
MannKind Corporation F1Q09 Earnings Call Transcript
Mon, May 4, 2009 • 2 Comments
MannKind Corporation Q4 2008 Earnings Call Transcript
Tue, Feb 17, 2009
MannKind Corporation Q3 2008 Earnings Call Transcript
Wed, Nov 5, 2008
MannKind Corporation Q2 2008 Earnings Call Transcript
Mon, Aug 11, 2008

MannKind Corporation Reports 2013 First Quarter Financial Results

Business Wire (May 9, 2013)
MannKind to Present at Bank of America Merrill Lynch 2013 Health Care Conference

Business Wire (May 8, 2013)
MannKind Corporation to Hold 2013 First Quarter Financial Results Conference Call on May 9, 2013

Business Wire (May 2, 2013)
MannKind Corporation to Present at the Cowen and Company 33rd Annual Health Care Conference

Business Wire (Feb 26, 2013)
MannKind Corporation Reports 2012 Fourth Quarter and Full Year Financial Results

Business Wire (Feb 11, 2013)
MannKind Corporation to Hold 2012 Fourth Quarter and Full Year Financial Results Conference Call on February 11, 2013

Business Wire (Feb 4, 2013)
MannKind Corporation to Present at The 31st Annual J.P. Morgan Healthcare Conference

Business Wire (Jan 3, 2013)
MannKind Corporation to Present at The 24th Annual Piper Jaffray Healthcare Conference

Business Wire (Nov 20, 2012)
Colby and MannKind Sign License and Joint Development Agreement to Develop and Commercialize Cancer Immunotherapy Products

Business Wire (Nov 13, 2012)
MannKind Corporation Reports 2012 Third Quarter Financial Results

Business Wire (Nov 1, 2012)
MannKind Corporation Reschedules 2012 Third Quarter Financial Results Conference Call to November 1, 2012 Due to Hurricane Sandy

Business Wire (Oct 29, 2012)
MannKind Corporation to Hold 2012 Third Quarter Financial Results Conference Call on October 29, 2012

Business Wire (Oct 22, 2012)
MannKind Announces Pricing of Public Offering of Common Stock and Warrants

Business Wire (Oct 18, 2012)
MannKind Receives Commitment from The Mann Group to Acquire 40,000,000 Shares of Common Stock and Warrants to Purchase Common Stock

Business Wire (Oct 18, 2012)
MannKind Announces Proposed Public Offering of Common Stock and Warrants

Business Wire (Oct 17, 2012)
MannKind Completes Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA

Business Wire (Oct 5, 2012)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Sep 4, 2012)
MannKind Corporation to Present at Upcoming Conferences

Business Wire (Sep 4, 2012)
MannKind Corporation Reports 2012 Second Quarter Financial Results

Business Wire (Aug 7, 2012)
MannKind Corporation to Hold 2012 Second Quarter Financial Results Conference Call on August 7, 2012

Business Wire (Jul 31, 2012)

MNKD vs. ETF Alternatives

Company Description

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead product candidate, AFRESA, is an ultra rapid-acting insulin that has completed Phase 3 clinical trials... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 22, 12:52 PM Midday top 10 gainers: CLNT +125%. MBND +24%. ZLC +24%. RCON +22%. MNKD +15%. NOA +15%. INSM +15%. SGOC +19%. CETV +14%. SKS +14%.
Midday top 10 Losers: STP -17%. LDK -14%. SWI -12%. MLP -11%. FXEN -12%. LAKE -10%. BALT -10%. DQ -10%. CSUN -9%. AMAG -9%. Comment! [On the Move]
Wednesday, May 22, 12:47 PM A takeover of MannKind (MNKD +15.9%) is "highly probable" SA contributor George Rho says, in an article published this morning which suggests $27.50/share as a ballpark figure (that's a 413% upside from Tuesday's close if you're inclined to keep score). Rho also notes that his "assumptions and projections would have to be considerably off the mark for the stock not to have substantial upside potential." Meanwhile, in the options market, an investor rolled a short position in January $5 strike calls up to the January $9 strike — 31K contracts traded at those two strikes this morning. Comment! [On the Move, Healthcare]
Wednesday, May 15, 12:04 PM MannKind Corporation (MNKD +6.4%) moves up again today after being initiated by MLV & Co. with a Buy and a $6 price target. The stock has been on a tear over the past few days, gaining over 25% since Friday on the back of in-line earnings report and positive comments out of its management on the progress of its Afrezza trials. Read more here: Earnings Call Transcript. 1 Comment [Healthcare, On the Move]
Friday, May 10, 3:50 PM For Mankind (MNKD +10.3%) no bad news is good news today, as the stock rips higher following an inline Q1 report late yesterday. Operating expenses rose by 9% Y/Y, primarily due to an increase in clinical trial related expenses. 2 Comments [Healthcare, Earnings, On the Move]
Thursday, May 9, 6:05 PM MannKind (MNKD): Q1 EPS of -$0.15 in-line. Shares +2.3% AH. (PR) 2 Comments [Earnings, Breaking News, Healthcare, On the Move]
Friday, April 12, 9:10 AM Premarket gainers: FST +12%. IOC +8%. WLT +7%. ASH +5%.
Losers: INFY -18%. HIMX -9%. MNKD -8%. Comment! [On the Move]
Friday, April 12, 8:14 AM Shares of Mannkind (MNKD) trade notably lower before the bell. In an article published Thursday evening, SA contributor Brian Wilson questions whether the company's key drug Afrezza can pass muster in Phase III clinicals. Shares -6.27% premarket. (The bullish thesis: Afrezza could be first-line therapy) 2 Comments [On the Move]
Friday, March 8, 8:17 AM MannKind (MNKD) gains 1.8% premarket as SA Pro author Joe Springer's bullish piece exits embargo. The company's Afrezza, currently in Phase III trials, could be the first-line drug therapy for type 2 diabetes - a disease now of pandemic size, he writes. 2 Comments [Healthcare, On the Move]
Monday, February 11, 4:14 PM More on MannKind (MNKD): Q4 EPS loss comes in below expectations on higher operating and R&D costs, primarily due to an adjustment in the fair value of a forward purchase contract and increased clinical trial related activities. Comment! [Healthcare, Earnings]
Monday, February 11, 4:02 PM Mannkind (MNKD): Q4 EPS of -$0.23 misses by $0.04. (PR) Comment! [Earnings, Breaking News, Healthcare]
Monday, February 11, 12:10 AM Notable earnings after Monday’s close: AMSC, BKD, BNNY, CRK, DNB, LGF, MAS, MNKD, NCLH, NQ, OMI Comment! [Earnings]
Sunday, February 10, 5:35 PM Notable earnings after Monday’s close: AMSC, BKD, BNNY, CRK, DNB, LGF, MAS, MNKD, NCLH, NQ, OMI 1 Comment [Earnings]
Wednesday, December 26, 2012, 12:52 PM Shares of MannKind (MNKD +5.7%) get a boost on a big vote of confidence from its Chairman and CEO Alfred Mann today, after the company revealed in a filing that he had recently purchased 40M shares at an average price of $2.59. The total price tag on the purchase: $103M. That brings Mann's total ownership in the company up to just under 75M shares. (SEC Form 4 Filing) 2 Comments [On the Move, Healthcare]
Tuesday, November 13, 2012, 10:00 AM MannKind (MNKD +1%) signs an agreement to give privately held Colby Pharmaceutical exclusive rights to develop and commercialize treatments based on MannKind's MKC1106, a potential immunotherapy for melanoma, prostate, hematological disorders and other cancers. Colby will pay MannKind up to $140M in up front and milestone payments, and then royalties on product sales. Comment! [Healthcare]
Thursday, November 1, 2012, 4:29 PM Mannkind (MNKD): Q3 EPS loss of -$0.22 beats by $0.02. Shares +2% AH. (PR) 1 Comment [Earnings, On the Move]
Thursday, November 1, 2012, 12:10 AM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]

k.dre
$MNKD i really dont understand how it goes up so much each day. each day i think it'll return to lower support, but nope!
Thu, 9:51 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

weed
To serve $MNKD...my favorite Twilight Zone episode.
Wed, 1:53 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nefas
I need a lot more conviction with the stocks i pick. $MNKD just exploded 1 week after i exited (i think)! gotta pay more attention!
Wed, 11:32 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

joebat
ohhh yeahh baby... That's a triple on $MNKD !!!!!!!
Wed, 11:32 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joe Springer
$MNKD Pretty sure that's a 52 week high : )
Wed, 10:47 AM
Reply (40)

• !Report Abuse
View all 40 replies
Icicle: Joe, with all the corruption at the FDA, wouldn't a buyout by a big name improve Afrezza's chances?
20 hours ago
• !Report Abuse
Joe Springer: That is what some think..
19 hours ago
• !Report Abuse
Add a reply...

140 characters

Clayton Rulli
$MNKD feel the squeeeeeze
Wed, 10:40 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joe Springer
$MNKD - That's a double. Just Sayin : ) http://seekingalpha.com/a/qw1h http://bit.ly/1098KoL
May 17, 10:59 AM
Reply (26)

• !Report Abuse
View all 26 replies
sheldond: Rule number one.....don't lose capital....same as rule two
Tue, 9:23 AM
• !Report Abuse
Nathaniel Munson: i agree with you on the core positions one absolutely, but you're right, biotech needs its own special rules
Tue, 9:33 AM
• !Report Abuse
Add a reply...

140 characters

Jason F
$MNKD Short Term Trading plan (longs &shorts pay attention): http://bit.ly/10H6y4k + Includes Charts & Price Targets
May 15, 6:53 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nefas
$MNKD took nice 6% in 2 days :)
May 15, 12:14 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

sheldond
$MNKD swing traders looking to take it to $6, MNKD meeting with BAC investors plus large short interest equals good things for long......
May 15, 9:30 AM
Reply (7)

• !Report Abuse
View all 7 replies
sheldond: Lets see what happens from the conference and if we can hold five.
May 15, 11:00 AM
• !Report Abuse
sheldond: There were a ton of penny grabbers this morning.
May 15, 11:02 AM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Joe Springer
$MNKD Pretty sure that's a 52 week high : )
Wed, 10:47 AM
Reply (40)

• !Report Abuse
View all 40 replies
Icicle: Joe, with all the corruption at the FDA, wouldn't a buyout by a big name improve Afrezza's chances?
20 hours ago
• !Report Abuse
Joe Springer: That is what some think..
19 hours ago
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - That's a double. Just Sayin : ) http://seekingalpha.com/a/qw1h http://bit.ly/1098KoL
May 17, 10:59 AM
Reply (26)

• !Report Abuse
View all 26 replies
sheldond: Rule number one.....don't lose capital....same as rule two
Tue, 9:23 AM
• !Report Abuse
Nathaniel Munson: i agree with you on the core positions one absolutely, but you're right, biotech needs its own special rules
Tue, 9:33 AM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD $4.56 in the after hours - new 52 week high!
May 10, 6:30 PM
Reply (11)

• !Report Abuse
View all 11 replies
Joe Springer: I think that's where they make a deal this year.
May 12, 5:07 PM
• !Report Abuse
retpdguy: Joe. You ok.
May 15, 8:00 PM
• !Report Abuse
Add a reply...

140 characters

sheldond
$MNKD swing traders looking to take it to $6, MNKD meeting with BAC investors plus large short interest equals good things for long......
May 15, 9:30 AM
Reply (7)

• !Report Abuse
View all 7 replies
sheldond: Lets see what happens from the conference and if we can hold five.
May 15, 11:00 AM
• !Report Abuse
sheldond: There were a ton of penny grabbers this morning.
May 15, 11:02 AM
• !Report Abuse
Add a reply...

140 characters

Nefas
Stocks i am watching next week $ZAGG, $MNKD, $HLF, $BBRY, $NOK, $MUX, $NBG, $PTIE, $PFE, $MTG..any suggestions ideas on my watchlist?
May 11, 10:02 AM
Reply (4)

• !Report Abuse
View all 4 replies
Seacap: I'm going to jump all over BBRY past 16.60
May 13, 12:24 AM
• !Report Abuse
Bigisbetter: DDD
May 14, 12:35 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - Who says mankind can't fly? MannKind basically said "all is going according to plan" and it jumps 10% on volume!
May 10, 2:12 PM
Reply (11)

• !Report Abuse
View all 11 replies
Joe Springer: Way to use strength and weakness my friend, stock market judo.
May 10, 3:00 PM
• !Report Abuse
vireoman: Kudos on the Jurassic Park joke. (Feeling justifiably giddy on the MNKD surge?)
May 10, 8:46 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD All good news, everything on time and new potential partners, after August data looks good for partnership, Al laughs loud every call!
May 9, 6:24 PM
Reply (4)

• !Report Abuse
View all 4 replies
TruffelPig: They are doing a very large stability study ;P
May 9, 8:25 PM
• !Report Abuse
sheldond: And study is two weeks longer for European standards.
May 9, 10:36 PM
• !Report Abuse
Add a reply...

140 characters

sheldond
$MNKD feels like bustin loose.....bustin loose!
May 2, 10:51 AM
Reply (2)

• !Report Abuse
View all 2 replies
LoveThisDat: Why do you say that?
May 2, 12:15 PM
• !Report Abuse
sheldond: Held over resistance of 4 and once options expire we should get our last big run.
May 2, 7:34 PM
• !Report Abuse
Add a reply...

140 characters

Kapitall
Insiders Are Buying 9 Environmentally Conscious Stocks $AMRS $ATSG $GHDX $MNKD $ODP $PHII $TRGT $VHI $VSAT http://seekingalpha.com/a/th4l
Apr 26, 4:08 PM
Reply (1)

• !Report Abuse
View all 1 replies
vireoman: So the spraying of Afrezza into one's nose evidently doesn't contribute to global warming?
Apr 27, 12:05 AM
• !Report Abuse
Add a reply...

140 characters

sheldond
$MNKD $4 options expire today! You do the math!! Hit pieces HMmmmmmmm? I flipped out half over four and added it all back in 3.80!!!
Apr 19, 10:39 AM
Reply (3)

• !Report Abuse
View all 3 replies
sheldond: It will not close over 4!!!
Apr 19, 10:55 AM
• !Report Abuse
sheldond: Well now I believe in efficiency.....
Apr 21, 8:54 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD Looks like a good day to buy courtesy of TheStreet.
Apr 18, 1:47 PM
Reply (13)

• !Report Abuse
View all 13 replies
sheldond: I'm sure it's just market efficiency ;)! This could make next few weeks fun!
Apr 19, 12:58 PM
• !Report Abuse
Joe Springer: I do think it sails..
Apr 19, 1:41 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - Submitted article RE: Feuerstine
Apr 17, 12:47 PM
Reply (3)

• !Report Abuse
View all 3 replies
sheldond: Check out my latest stock talk about mnkd or just consider all the options at 4.00 that might expire. Do we end at today 3.97 or 3.99!
Apr 19, 10:42 AM
• !Report Abuse
sheldond: The market is so efficient. You were smart to convert. I prefer flipping but hey everyone has a style!
Apr 19, 10:43 AM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - Hey-O! http://bit.ly/10ictCA #adamfeuerstein #thestreet
Apr 17, 6:56 PM
Reply (1)

• !Report Abuse
View all 1 replies
sheldond: Captain Pacard of the USS Veritas! Aiming at the propaganda submarine.....Direct hit!!!
Apr 17, 10:58 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD Approval should come easy for Afrezza: http://seekingalpha.com/a/sqql
Apr 15, 6:15 AM
Reply (5)

• !Report Abuse
View all 5 replies
vireoman: I welcome thoughtful, intelligent counter-arguments. Neither of those two recent articles fit the bill. Kudos on your well-reasoned rebuttal
Apr 15, 9:24 PM
• !Report Abuse
Joe Springer: Thank you vireoman, I want to just republish my original article but I can't.
Apr 15, 9:38 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
$MNKD - I'll see if I can get an article out tonight rebutting the one today.
Apr 12, 12:13 PM
Reply (7)

• !Report Abuse
View all 7 replies
Joe Springer: Thanks, I'm a little busy but I'll get it done this weekend.
Apr 12, 10:56 PM
• !Report Abuse
sheldond: No rush....the truth will set them free. This is merely a stock event not a business event. The catalyst is coming and no one can stop it!
Apr 13, 12:19 PM
• !Report Abuse
Add a reply...

140 characters

MNKD MannKind Corporation

MNKD

MannKind Corporation